MDCO-216

Product Overview

In December of 2009, we obtained an exclusive worldwide license to MDCO-216 (ApoA-I Milano), an investigational product. MDCO-216 is a naturally occurring variant of a protein found in human high-density lipoprotein (HDL).  Based upon multiple non-clinical studies and a Phase 1/2 clinical trial of MDCO-216 conducted prior to our license of this product candidate, we believe that MDCO-216 has the potential to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS. We have completed the technology transfer for the drug and expect to commence clinical studies sometime in 2011.